

## ELREXFIO (elranatamab) Patient Card

Carry this card with you at all times. **SHOW THIS CARD** to any healthcare provider involved in your care and if you go to the emergency room.

### IMPORTANT SAFETY INFORMATION FOR PATIENTS RECEIVING TREATMENT WITH ELREXFIO:

#### FOR THE PATIENT

**Call your healthcare provider or get emergency help right away if you have any of these symptoms:**

Fever (38°C or higher)	Confusion
Difficulty breathing	Feeling less alert
Chills	Trouble speaking or writing
Headache	Numbness and tingling (feeling like "pins and needles") or loss of feeling
Low blood pressure	
Feeling dizzy	
Fast heartbeat	
Increased level of liver enzymes in the blood	

**YOU SHOULD ALWAYS ASK YOUR DOCTOR ABOUT TAKING OTHER MEDICATIONS WHILE TAKING ELREXFIO.**



**IMPORTANT TO REMEMBER:** You may be asked to remain within proximity of a healthcare facility so your healthcare provider can monitor you for signs and symptoms daily for 48 hours after administration of the first step-up dose, and for 24 hours after administration of the second step-up dose. If you have any of these symptoms call your doctor or seek emergency medical attention right away! These are not all of the possible symptoms of ELREXFIO. Tell your doctor if you have any symptom that bothers you or does not go away.

 **Breakthroughs that change patients' lives®**

Pfizer Scientific Technical Limited Company  
Al Riyadh – Al Aqeeq Dis.  
King Abdullah Financial District, Building 4.07  
Postal Code 13519  
Tel: +966 12 2293500  
Fax: +966 12 2293692

## FOR HEALTHCARE PROVIDERS

**IMPORTANT SAFETY INFORMATION YOU SHOULD KNOW:** ELREXFIO therapy can cause cytokine release syndrome (CRS) or neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) which may be fatal or life threatening. CRS may involve multiple organ systems.



## THIS PATIENT HAS RECEIVED ELREXFIO.

Name of ELREXFIO Treating Oncologist: .....

Office Phone Number: .....

After Hours Phone Number: .....

Healthcare Setting Name: .....

### Dates of ELREXFIO Injections:

- Step-up Dose 1 .....
- Step-up Dose 2 .....
- First Full Dose .....

## ADVERSE EVENTS REPORTING:

Suspected adverse reactions should be reported to:

- The National Pharmacovigilance & Drug safety Centre (NPC) at Saudi Food and Drug Authority (SFDA)

- Pharmacovigilance Department in the company

E-mail: [SAU.AEReporting@pfizer.com](mailto:SAU.AEReporting@pfizer.com)

SFDA Call Center: 19999

Toll-Free Phone: 8002490000

Fax: +966-11-2057662

E-mail: [npc.drug@sfd.gov.sa](mailto:npc.drug@sfd.gov.sa)

Website: <http://ade.sfd.gov.sa/>

*For extra copies, please send an email with your contact details and the required amount to [SAU.AEReporting@pfizer.com](mailto:SAU.AEReporting@pfizer.com)*